Format

Send to

Choose Destination
Nat Rev Cancer. 2008 Sep;8(9):714-24. doi: 10.1038/nrc2401.

Tailoring to RB: tumour suppressor status and therapeutic response.

Author information

1
Department of Cancer Biology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA. eknudsen@kimmelcancercenter.org

Abstract

The retinoblastoma tumour suppressor (RB) is a crucial regulator of cell-cycle progression that is invoked in response to a myriad of anti-mitogenic signals. It has been hypothesized that perturbations of the RB pathway confer a synonymous proliferative advantage to tumour cells; however, recent findings demonstrate context-specific outcomes associated with such lesions. Particularly, loss of RB function is associated with differential response to wide-ranging therapeutic agents. Thus, the status of this tumour suppressor may be particularly informative in directing treatment regimens.

PMID:
19143056
PMCID:
PMC2914856
DOI:
10.1038/nrc2401
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center